RxDoctor Payments Data

Amy Gandhi, MD

Internal Medicine · Sugar Land, TXNPI 1053844233

Payments from drug & device makers

$1,059in general payments, 2019–2025

Across 76 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$598
  • Paratek Pharmaceuticals, Inc.$97
  • Pfizer$84
  • Lilly USA, LLC$47
  • Shield Therapeutics Inc$35
  • Eisai Inc.$33
  • plus $166 from 8 others

What the payments were for

  • Food & beverage$1,04298%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,059 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$44,750
Medicare patients
109
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$53,375
EliquisApixaban30$37,847
JardianceEmpagliflozin28$33,826
JanuviaSitagliptin Phosphate21$29,454
TrulicityDulaglutide14$22,681
LinzessLinaclotide13$15,693
FarxigaDapagliflozin Propanediol14$14,217
MounjaroTirzepatide13$13,829
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,144
Memantine Hcl14$3,747
Nifedipine ErNifedipine62$2,020
Omega-3 Acid Ethyl Esters23$1,893
Gabapentin79$1,616
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,611
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$1,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$53,37549 claims
PfizerEliquis$84$37,84730 claims
Lilly USA, LLCTrulicity, Mounjaro$47$36,51027 claims
MerckJanuvia$22$29,45421 claims
AbbVieLinzess$598$15,69313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →